Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
$18.16
$0.28(1.32%)
At close: 4:00 PM EST
$18.16
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$10.57 - $25.48
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.52M
Market Cap
$2.64B
Enterprise Value$1.70B
Total Cash (Recent Filing)$848.20M
Total Debt (Recent Filing)$44.40M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Mar 02, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding146,661,830
10 Day Avg. Volume1,507,036
30 Day Avg. Volume1,520,942
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.73
Price to Sales (P/S)0.00
P/FCF Ratio-9.22
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.19
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$31.00Price Target Upside70.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth StrategyDenali announced its D3 strategy to discover, develop, and deliver on its TV platform, indicating a clear plan for future growth.
Pipeline ExpansionThe company continues to execute on expanding its clinical pipeline, achieving its target of bringing two preclinical assets forward in 2025, with an additional one to two targeted annually moving forward.
Regulatory DevelopmentsDenali Therapeutics is experiencing positive regulatory developments that support its lead program, tividenofusp alfa, which has the potential to become a commercially disruptive program for Hunter's disease patients.
Bears Say
Clinical Program SetbacksThere have been some setbacks with a priority review voucher now not expected or included in financial guidance if tivi is approved and the Pompe clinical programs being placed on FDA clinical hold.
Leadership ChangesThe departure of Chief Medical Officer Carole Ho may be seen as a negative factor, although Dr. Peter Chin has been named Acting CMO and Head of Development.
Regulatory DelaysThe recent delay in the 310 regulatory process resulted in a new PDUFA date of April 5th.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $25.48 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $2.64B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 80 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.748 by $0.008.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.75.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 146,661,830 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.748. Following the earnings report the stock price went up 4.233%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (70.70% Upside)
$31.00 (70.70% Upside)
Hedge Fund Trend
Increased
By 114.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.32%
12-Months-Change
Fundamentals
Return on Equity
-44.44%
Trailing 12-Months
Asset Growth
-27.40%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases, such as Alzheimer's, Parkinson's, and ALS. The company operates in the biotechnology sector, leveraging its expertise in the biology of neurodegeneration to create a diverse pipeline of product candidates. Denali's core services include the development of small molecules, antibodies, and other therapeutic modalities aimed at addressing the underlying mechanisms of neurodegenerative conditions.
DNLI Stock 12 Month Forecast
Average Price Target
$31.00
▲(70.70% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
7.13% Insiders
29.13% Mutual Funds
35.42% Other Institutional Investors
12.98% Public Companies and
Individual Investors